Medicare ESRD Reimbursement: A Call for Reform and Innovation
In Washington, D.C., the Medicare reimbursement structure for chronic kidney disease (CKD) and end-stage renal disease (ESRD) came under scrutiny by the Ways and Means Health Subcommittee during a recent hearing. Concerns arose over policies hindering innovative treatments that could enhance patient outcomes. Medicare allocates $50 billion annually for kidney care, representing 7% of expenditures while covering only 1% of beneficiaries. The ESRD payment bundle promotes market consolidation in dialysis services, discouraging innovation and limiting advancements in treatment options.
Medicare currently covers only four new ESRD drugs, two of which are not widely available, alongside one new medical device. Additionally, there is a lack of incentives for proactive measures such as at-home dialysis, early screenings, and kidney transplants, which could significantly improve patient care and quality of life.
Early Detection and Preventive Care
Dr. Suzanne Watnick, a nephrology expert, emphasized the importance of early detection: “Nine out of 10 people with kidney diseases aren’t aware that they have it. Anything we can do to ensure that upstream care is recognized is a benefit,” she asserted. This highlights how the U.S. health system inadequately addresses early-stage kidney disease, predominantly linked to preventable conditions like diabetes and hypertension.
Only 15% of dialysis patients receive treatment at home, despite evidence showing benefits like quicker recovery and higher survival rates. Witness testimony outlined the difficulties for rural patients traveling long distances for in-center dialysis. Ashli Littleton, a home dialysis patient, shared the profound impact of at-home treatment: “It allowed me to be able to see my kids every day, which is the best part of my day.”
Financial Barriers to Innovation
The ESRD "payment bundle" poses a financial barrier to innovation, as dialysis providers receive a flat fee for services that often fails to cover novel drug costs. Dr. John P. Butler, CEO of Akebia Therapeutics, cited a Nobel Prize-winning drug for ESRD-related anemia treatment that could significantly reduce hospitalization costs but is excluded from the payment bundle.
Rep. Claudia Tenney stressed the need for integrated care prioritizing early detection over prolonged dialysis treatments. Dr. Robert Taylor, Chief Medical Officer at DCI, discussed the financial implications, noting that nephrologists benefit more financially from dialysis than managing early-stage kidney disease. Taylor stated, “Advanced kidney disease may cost Medicare $35,000 to $40,000 per year per patient, whereas dialysis costs rise to $90,000 to $95,000 annually.”
The hearing aims to address systemic issues in kidney care financing and delivery, pursuing reforms to enhance preventive care, foster treatment innovation, and reduce costs while improving patient outcomes.